(NASDAQ: CAPR) Capricor Therapeutics's forecast annual revenue growth rate of 11.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.98%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.26%.
Capricor Therapeutics's revenue in 2024 is $27,152,218.On average, 2 Wall Street analysts forecast CAPR's revenue for 2024 to be $623,120,510, with the lowest CAPR revenue forecast at $598,716,312, and the highest CAPR revenue forecast at $647,524,707. On average, 2 Wall Street analysts forecast CAPR's revenue for 2025 to be $935,494,238, with the lowest CAPR revenue forecast at $732,125,925, and the highest CAPR revenue forecast at $1,138,862,550.
In 2026, CAPR is forecast to generate $1,225,090,715 in revenue, with the lowest revenue forecast at $1,197,432,624 and the highest revenue forecast at $1,252,748,805.